急性结膜炎患者治疗前后血清hs-CRP、Il-6和β-防御素-3检测的临床意义被引量：2

Clinical significance of measurement of changes of serum hs-CRP. Il-6 and beta-defensin-3 levels after treatment in patients with acute conjunctivitis

下载PDF

导出

摘要目的探讨急性结膜炎患者治疗前后血清hs-CRP、Il-6和β-防御素-3水平的变化及临床意义。方法应用免疫比浊法,放射免疫分析法和酶联法对40例急性结膜炎患者进行了血清hs-CRP、Il-6和β-防御素-3的水平检测,并与35名正常健康人作比较。结果急性结膜炎患者在治疗前血清hs-CRP、Il-6水平非常显著地高于正常人组(P<0.01),而β-防御素-3水平显著地低于正常人组(P<0.01),经中西医结合治疗2周后则与正常人比较无显著性差异(P>0.05)。结论检测急性结膜炎患血清hs-CRP、Il-6和β-防御素-3水平的变化对临床观察预后均有重要的临床价值。 Objective To explore the clinical significance of serum hs-CRP, Il-6 and beta-defensin-3 levels in patients with acute conjunctivitis after treatment .Methods Serum hs-CRP （ with immumo-turbidity ） Serum Il-6（with RIA）, Serum beta-defensin-3（with ElisA） levels were measured in 40 patients with acute conjunctivitis before and after treatment as well as in 35 controls.Results Before treatment , Serum Il-6, hs-CRP levels in the patients were significantly higher than those in controls （P〈0.01）,but Serum beta-defensin-3 levels were significantly lower（P〈0.01）.After treatment for 2 weeks, there were no significance between the levels in patients and controls （P〉0.05）.Conclusions Detection of serum hs-CRP, Il-6 and bata-defensin-3 levels after treatment might be important for outcome prediction in patients with acute conjumctivitis .

作者熊杰刘忠伦

机构地区江苏省连云港市第一人民医院

出处《齐齐哈尔医学院学报》 2014年第20期3000-3001,共2页 Journal of Qiqihar Medical University

关键词急性结膜炎超敏C-反应蛋白白细胞介素-6 β-防御素-3 Acute conjunctivitis High-sensitive C reactive protein （hs-CRP） Terleuk in-6 （11-6） Beta-defensin-3

分类号 R541.4 [医药卫生—心血管疾病]

引文网络
相关文献

参考文献4

1聂海,祝之明,闫振成,倪银星,赵志钢,张刚,杨华.高敏C反应蛋白与代谢综合征组分及靶器官损害的关系[J].中华心血管病杂志,2004,32(12):1113-1117. 被引量：62
2Semple CA, Taylor K, Eastwood H, et al. Beta-defensin, evolution selection complexity and clues for residues of fcmctional importance [J]. Siochen soe Trans,2006,34(2):257-262.
3Ross R. Atheroslerosis-Am inflammatory diseases[ J ]. N. Eng med, 1999,340:115-118.
4袁伟杰,郭峰.细胞因子与肾小球肾炎[J].上海免疫学杂志,1992,12(3):191-192. 被引量：47

二级参考文献21

1Laaksonen DE, Niskanen L, Punnonen K, et al. Sex hormones, inflammation and the metabolic syndrome: a population-based study. Eur J Endocrinol, 2003, 149: 601-608.
2Pradhan AD, Cook NR, Buring JE, et al. C-reactive protein is independently associated with fasting insulin in nondiabetic women.Arterioscler Thromb Vasc Biol, 2003, 23: 650-655.
3Freeman DJ, Norrie J, Caslake MJ, et al. C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes, 2002, 51: 1596-1600.
4Ridker PM, Rifai N, Rose L, et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med, 2002, 347: 1557-1565.
5Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA,2001, 285: 2486-2497.
6Stuveling EM, Bakker SJ, Hillege HL, et al. C-reactive protein modifies the relationship between blood pressure and microalbuminuria. Hypertension, 2004, 43:791-796.
7Devaraj S, Xu DY, Jialal I. C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: implications for the metabolic syndrome and atherothrombosis. Circulation, 2003, 107: 398-404.
8Devereux RB, Alonso DR, Lutas EM, et al.Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol, 1986, 57: 450-458.
9Tan CE, Chew SK, Ma S, et al. Can we apply the National Cholesterol Education Program Adult Treatment Panel definition of the metabolic syndrome to Asians? Diabetes Care, 2004, 27:1182-1186.
10Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation, 2003,107: 363-369.